Sign in
CompletedEarly phase 1

Effects of 4-AP on Functional SCI Recovery

Key facts

Who runs it
Shirley Ryan AbilityLab
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
26 people enrolled
Started
30 Jun 2022
Ended
30 Jun 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dalfampridine
  • Placebo drug
  • STDP stimulation
  • Exercise training
Record updated
3 June 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Male and females between ages 18-85 years
  • SCI at least 4 weeks post injury
  • Spinal Cord injury at or above L2
  • ASIA A,B,C, or D, complete or incomplete
  • Possess the following abilities
  • The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles

Who cannot take part

  • Any debilitating disease prior to the SCI that caused exercise intolerance
  • Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
  • Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
  • Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
  • Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
  • Any history of renal impairment
  • History of head injury or stroke
  • Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
  • History of seizures or epilepsy
  • If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
  • Premorbid, ongoing major depression or psychosis, altered cognitive status
  • Pregnant females
  • Metal plate in skull

Where in United States

  • Shirley Ryan AbilityLabChicago, United States

About the trial

What the trial wants to find out

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

The 3 groups in the trial

  • Dalfampridine (4-AP)+STDP+trainingExisting treatment, for comparison

    The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of 4-AP, STDP stimulation and training.

    Treatment: Dalfampridine, STDP stimulation, and Exercise training

  • Placebo+STDP+trainingPlacebo, for comparison

    The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of placebo drug, STDP stimulation and training.

    Treatment: Placebo drug, STDP stimulation, and Exercise training

  • Dalfampridine (4-AP)+STDP+training for extended sessionsTreatment being tested

    The long-term effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of 4-AP, STDP stimulation and training.

    Treatment: Dalfampridine, STDP stimulation, and Exercise training

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of 4-AP on Functional Recovery After Spinal Cord Injury
Record updated
3 June 2026